PT - JOURNAL ARTICLE AU - Spitzer, Avishay AU - Gritsch, Simon AU - Weisman, Hannah R. AU - Gonzalez Castro, L. Nicolas AU - Nomura, Masashi AU - Druck, Nicholas AU - Chanoch-Myers, Rony AU - Lee, Christine K. AU - Nagashima, Hiroaki AU - Miller, Julie J. AU - Arrillaga-Romany, Isabel AU - Louis, David N. AU - Wakimoto, Hiroaki AU - Pisano, Will AU - Wen, Patrick Y. AU - Ligon, Keith L. AU - Cahill, Daniel P. AU - Suvà, Mario L. AU - Tirosh, Itay TI - Mutant IDH Inhibitors Induce Lineage Differentiation in IDH-mutant Oligodendroglioma AID - 10.1101/2021.11.16.21266364 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.16.21266364 4099 - http://medrxiv.org/content/early/2021/11/20/2021.11.16.21266364.short 4100 - http://medrxiv.org/content/early/2021/11/20/2021.11.16.21266364.full AB - Recent data showed promising signs of objective tumor responses in subsets of patients with low grade glioma treated with inhibitors of mutant IDH (IDHi) (1). However, the molecular and cellular underpinnings of such responses are not known. Here, we profiled 6,039 transcriptomes by single-cell or single-nucleus RNA-sequencing isolated from three IDH-mutant oligodendroglioma patients with clinical response to IDHi. Importantly, the tissues were sampled on-drug, four weeks from treatment initiation and our dataset includes a matched pre- and on-treatment sample pair. We integrate our findings with analysis of 8,241 transcriptomes from seven untreated samples, 134 bulk samples from the TCGA and experimental models.(2,3) We find that IDHi treatment induces a robust differentiation towards glial lineages, accompanied by a depletion of stem-like cells and a reduction of cell proliferation. Our study provides the first evidence in patients of the differentiating potential of IDHi on the cellular hierarchies that drive oligodendrogliomas.Competing Interest StatementM.L.S. is equity holders, scientific co-founder and advisory board member of Immunitas Therapeutics. I.T. is advisory board member of Immunitas Therapeutics. D.P.C. has consulted for Lilly and Boston Pharmaceuticals, and has received honoraria and travel reimbursement from Merck for invited lectures. The authors declare that such activities have no relationship to the present study.Funding StatementThis work was supported by a Broad Institute Israel Science Foundation Collaborative Project Award (I.T. and M.L.S.), the MGH Research Scholars Award (M.L.S.), grants from the Mark Foundation Emerging Leader Award (M.L.S.), the Sontag Foundation Distinguished Scientist Award (M.L.S.), N.I.H. R37CA245523 (M.L.S) and R01CA258763 (M.L.S.). I.T. is the incumbent of the Dr. Celia Zwillenberg-Fridman and Dr. Lutz Zwillenberg Career Development Chair, and is supported by the Zuckerman STEM Leadership Program, the Mexican Friends New Generation, the Benoziyo Endowment Fund, and grants from the Human Frontiers Science Program. A.S. is partially supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center, and by a research grant from the Estate of Tully and Michele Plesser.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board 10-417 of Dana-Farber Harvard Cancer Center gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for untreated patients produced in the present study are available upon reasonable request to the authors. All data for IDHi-treated patients produced in the present study will be made available at a later time.